Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

[Viral clearance in wild-type hepatitis B virus after treatment with pegylated interferon alpha-2a].

López López MP, Rincón Fuentes JP, Rabell Iñigo S, González Pérez-Crespo C, Rodríguez Gil FJ, Jorge Vidal V, Morán Sánchez S, Nicolás Del Prado MI.

Gastroenterol Hepatol. 2008 Nov;31(9):625-6. Spanish. No abstract available.

PMID:
19091259
2.

Idiopathic hepatitis B surface antibody seroreversion after pegylated interferon alpha-2a therapy.

Tsynman DN, Rivera R, Maliakkal B.

J Gastrointestin Liver Dis. 2013 Mar;22(1):110-1. No abstract available.

3.

Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a.

Chen J, Wang Z, Guo Y, Peng J, Sun J, Ahmed CS, Zhou Y, Hou J.

Antiviral Res. 2009 Jan;81(1):88-91. doi: 10.1016/j.antiviral.2008.09.005. Epub 2008 Oct 21.

PMID:
18948141
5.

Treatment of hepatitis B with interferon and combination therapy.

Cooksley WG.

Clin Liver Dis. 2004 May;8(2):353-70. Review.

PMID:
15481344
6.

Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B.

Rossetti B, Bianco C, De Luca A.

Infection. 2012 Jun;40(3):347-9. doi: 10.1007/s15010-011-0198-1. Epub 2011 Oct 15. No abstract available.

PMID:
22002731
7.

Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.

Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.

J Gastrointestin Liver Dis. 2009 Dec;18(4):425-31.

8.

Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.

Jinato T, Chuaypen N, Poomipak W, Praianantathavorn K, Makkoch J, Kiatbumrung R, Jampoka K, Tangkijvanich P, Payungporn S.

Exp Biol Med (Maywood). 2016 Oct;241(16):1803-10. doi: 10.1177/1535370216647184. Epub 2016 May 4.

9.

Peginterferon and lamivudine for hepatitis B.

Assy NN, Hussein O.

N Engl J Med. 2004 Dec 30;351(27):2879; author reply 2879. No abstract available.

PMID:
15625344
10.

[Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].

Yang F, Wu XF, Li XH, Wei N.

Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):950-1. Chinese. No abstract available.

PMID:
20038343
11.

Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.

Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.

Neth J Med. 2008 May;66(5):191-5.

12.

Early virologic response to pegylated interferon in chronic hepatitis B infection.

Ladep NG, Ugiagbe RA, Okonkwo U, Okeke EN, Malu AO.

Niger J Med. 2009 Jul-Sep;18(3):330-1.

PMID:
20120656
13.

The maze of treatments for hepatitis B.

Lok AS.

N Engl J Med. 2005 Jun 30;352(26):2743-6. No abstract available.

PMID:
15987924
14.

[Interferon therapy for chronic hepatitis B].

Tang WL, Xie Q.

Zhonghua Gan Zang Bing Za Zhi. 2009 Oct;17(10):726-9. Chinese. No abstract available.

PMID:
19874685
15.

Looking to the future: new agents for chronic hepatitis B.

Dienstag JL.

Am J Gastroenterol. 2006;101 Suppl 1:S19-25. Review.

PMID:
16448448
16.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.

N Engl J Med. 2005 Jun 30;352(26):2682-95.

17.

Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.

Song K, Rajvanshi P.

N Engl J Med. 2005 Oct 13;353(15):1630-1; author reply 1630-1. No abstract available.

19.

[Results of 2 years of interferon treatment in HBeAg positive chronic hepatitis B].

Hu LH, Long XZ, Tang CL.

Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):940-1. Chinese. No abstract available.

PMID:
20038338
20.

Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?

Cooksley G.

Nat Clin Pract Gastroenterol Hepatol. 2005 Jan;2(1):12-3. No abstract available.

PMID:
16265091

Supplemental Content

Support Center